Platform study of circulating tumor DNA–directed adjuvant chemotherapy in colon cancer (CLAUDIA Colon Cancer, KCSG CO22-12). A precision medicine trial leveraging tissue and blood-based tumor genomics ...

Noting that adding bevacizumab to 1L chemotherapy for stage III/IV epithelial ovarian cancer significantly improved progression‐free survival in clinical trials, Linda R. Duska, M.D., M.P.H ...

Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b/2 study in advanced MSS CRC. This is an ASCO Meeting Abstract from the ...

These results were presented at a conference in 2019. In this trial, the researchers looked at the drugs bevacizumab, gemcitabine and pegylated liposomal doxorubicin. Bevacizumab (Avastin) is a ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

A final long-term analysis did not find an overall survival benefit associated with bevacizumab in the full patient cohort. To investigate whether these findings also hold true in real-world ...

ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...

The overall response rate was 100%, and the intracranial response rate was 85.7%. First-line treatment with alectinib and bevacizumab appears to be effective for patients with ALK-rearranged ...

MONDAY, May 12, 2025 (HealthDay News) — The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic ...